{
    "clinical_study": {
        "@rank": "151393", 
        "acronym": "COMFORT", 
        "arm_group": [
            {
                "arm_group_label": "OnabotulinumtoxinA", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA (BOTOX\u00ae) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable)."
            }, 
            {
                "arm_group_label": "Placebo/OnabotulinumtoxinA", 
                "arm_group_type": "Other", 
                "description": "Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable)."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX\u00ae) compared\n      with placebo, in achieving a 100% reduction in urinary incontinence in patients with\n      overactive bladder (OAB) not properly managed with an anticholinergic."
        }, 
        "brief_title": "OnabotulinumtoxinA (BOTOX\u00ae) Treatment for Urinary Incontinence in Patients With Overactive Bladder", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Overactive Bladder", 
        "condition_browse": {
            "mesh_term": [
                "Urinary Incontinence", 
                "Urinary Bladder, Overactive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Patients with symptoms of Overactive Bladder (OAB) (frequency and urgency) with urinary\n        incontinence for at least 6 months prior to screening.\n\n        Exclusion Criteria:\n\n          -  Symptoms of OAB due to a neurological reason\n\n          -  Use of anticholinergics or other medications or therapies to treat symptoms of OAB\n             within 7 days of screening\n\n          -  Use of Clean Intermittent Catheterization (CIC) or indwelling catheter to manage\n             urinary incontinence\n\n          -  Use of botulinum toxin therapy of any serotype for any urological condition\n\n          -  Use of botulinum toxin therapy of any serotype for any non-urological condition in\n             the 12 weeks prior to screening\n\n          -  History of any pelvic or urological abnormalities, bladder surgery or disease, other\n             than OAB, that may affect bladder function\n\n          -  Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, or Amyotrophic Lateral\n             Sclerosis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "258", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01945489", 
            "org_study_id": "GMA-OAB-113"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "OnabotulinumtoxinA", 
                    "Placebo/OnabotulinumtoxinA"
                ], 
                "description": "OnabotulinumtoxinA (BOTOX\u00ae) injected into the detrusor.", 
                "intervention_name": "onabotulinumtoxinA", 
                "intervention_type": "Biological", 
                "other_name": [
                    "BOTOX\u00ae", 
                    "botulinum toxin Type A"
                ]
            }, 
            {
                "arm_group_label": "Placebo/OnabotulinumtoxinA", 
                "description": "Normal saline (placebo) injected into the detrusor.", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Shreveport", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mountlake Terrace", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of Participants who Achieve a 100% Reduction in Urinary Incontinence Episodes", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Change from Baseline in Number of Episodes of Urinary Incontinence", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01945489"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "King's Health Questionnaire (KHQ) domain scores", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of Micturition Episodes", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of Daily Urgency Episodes", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of Nocturia Episodes", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}